Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study
Amgen, Boeing Share Losses Lead Dow's 200-Point Fall
Merck & Co. (MRK) Fell As It Faced Some Demand Headwinds In China
Daily short sale tracking: Nu Holdings's short volume increased by 25 million, with a short sale ratio of 31%
Nu Holdings(NU.US) ranked top of the list had the largest change in short volume (25.32 million shares), and the short volume ratio of QXO Inc(QXO.US) reached 44.93%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Dr. Reddy's Laboratories Launches Anti-Parasitic Drug Ivermectin
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $150
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
Today's Analyst Rating | UnitedHealth Price Target Raised to $655 by RBC Capital, Citi Upgrades Chevron to Buy
Nov 26, Wall Street analysts have updated their stock ratings today including $UnitedHealth(UNH.US)$ and $Chevron(CVX.US)$.
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123
Merck & Co. Hold Rating: Balancing Promising Trial Results With Market Dynamics and Future Uncertainties
Merck's "first-in-class" therapy Winrevair (sotatercept) achieves Phase 3 clinical primary endpoints.
Winrevair is a first-in-class type II Activin receptor (ActRIIA) fusion protein.
BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $136
Nike, Sherwin-Williams Co. Share Gains Lead Dow's Nearly 250-Point Jump
Why Is Merck Stock Trading Higher On Monday?
Express News | Merck Shares up 2% After Therapy for Rare Lung Condition Showed Reduced Risk of Death in Study
Express News | Merck & Co Inc : Jefferies Raises Target Price to $150 From $149
Guggenheim Maintains Merck & Co(MRK.US) With Buy Rating
Hanmi Pharmaceutical Y Beijing Hanmi Avanzan En Los Ensayos Clínicos Del BH3120 Como Inmunoterapia
Merck Heart Disease Drug Meets Target in Phase 3 Study